rybelsus a glp 1 Day 5: (Oral Semaglutide) Class: GLP-1 receptor agonist Avg Weight Loss: 5–10% FDA Approved: 2019 for T2DM; being studied for obesity Pros: First oral GLP-1 agonist Non-injection option Effective for blood Drugstore Options:1 Bottle 40% of GLP-1 Volume

rybelsus a glp 1 Day 5: (Oral Semaglutide) Class: GLP-1 receptor agonist Avg Weight Loss: 5–10% FDA Approved: 2019 for T2DM; being studied for obesity Pros: First oral GLP-1 agonist Non-injection option Effective for blood Drugstore Options:1 Bottle 40% of GLP-1 Volume

40% of GLP-1 Volume Shifts to Direct Manufacturers Approximately 40% of GLP- 1 drug volume now moves through direct manufacturer channels like LillyDirect, bypassing traditional pharmacy benefit managers. This shift is disrupting the

doi: 10.1007/s40265-024-02029-0 38 ZhangYLZhouCLiXFYangMNTaoLZhengXYet al

Drugstore

Options:1 Bottle

Its demonstrated small effects on body weight and body fat by otherwise minimal impact on other metabolic markers as shown in humans make it a proper sugar replacer, potentially useful in weight management